Overview

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see what effects (good and bad) treatment with abiraterone acetate (an oral hormonal agent) and prednisone (a steroid) with and without cabazitaxel (a chemotherapy) have on the cancer and to find out more about whether specific laboratory tests on tumor are useful in predicting how the patient will respond to treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

Sanofi
Thomas Jefferson University
Weill Medical College of Cornell University

Treatments:

Abiraterone Acetate
Prednisone